Interleukin Genetics, Inc. to Present at Biotech Showcase™ 2012

01/09/2012

WALTHAM, Mass.-- Interleukin Genetics, Inc. (OTCQB: ILIU.PK - News) announced today that CEO Lewis H. Bender will present at the Biotech Showcase™ 2012 at the Wyndham Parc 55 Hotel, 55 Cyril Magnin Street in San Francisco. The presentation is scheduled for Wednesday, Jan. 11 at 11:00 a.m. (PST) in the hotel’s Mission II room, located on the fourth floor. Mr. Bender will be available for one-on-one meetings with investors participating in the Biotech Showcase before and after his presentation.

About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB: ILIU.PK - News) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

Contact:
Media:
Schwartz MSL Boston
Jon Siegal / Kirsten Fallon, 781-684-0770
interleukin@schwartzmsl.com
or
Investors:
Interleukin Genetics, Inc.
Eliot M. Lurier, CFO, 781-398-0700
elurier@ilgenetics.com